quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:01:00·44d
PRRelease
Precision BioSciences Inc. logo

Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

DTIL· Precision BioSciences Inc.
Health Care
Original source

Companies

  • DTIL
    Precision BioSciences Inc.
    Health Care

Recent analyst ratings

  • Jan 10UpdateBMO Capital Markets$34.00
  • Apr 30UpdateGuggenheim$19.00
  • Jun 17UpdateBMO Capital Markets$7.00
  • Jun 9UpdateWilliam Blair-
  • Sep 10UpdateStifel$26.00

Related

  • SEC15d
    SEC Form DEFA14A filed by Precision BioSciences Inc.
  • SEC15d
    SEC Form DEF 14A filed by Precision BioSciences Inc.
  • PR15d
    Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
  • SEC27d
    SEC Form PRE 14A filed by Precision BioSciences Inc.
  • PR36d
    iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission
  • SEC37d
    Precision BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • SEC42d
    SEC Form 10-K filed by Precision BioSciences Inc.
  • SEC42d
    Precision BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022